Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03562975 · ClinicalTrials.gov registry record
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
A clinical trial, sponsored by University of South Florida.
- Completed
- Registry status
- 18
- Enrollment target
NCT03562975 is a clinical trial that has completed, run by University of South Florida. The registered enrollment target is 18 participants.
The verdict
NCT03562975 has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2023-01-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03562975
The ClinicalTrials.gov registry entry for NCT03562975 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT03562975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03562975 about?
NCT03562975 is a clinical study titled "Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus". The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
What is the current status of trial NCT03562975?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2018-07-23. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT03562975?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT03562975?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.